Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures

作者: Lisa M. Baker , Anthony Aimon , James B. Murray , Allan E. Surgenor , Natalia Matassova

DOI: 10.1038/S42004-020-00367-0

关键词:

摘要: … of these weak binding fragments to hit and lead compounds. We have developed an approach … This approach can transform early hit to lead optimisation and the lessons learnt from this …

参考文章(38)
Vicki L. Nienaber, Paul L. Richardson, Vered Klighofer, Jennifer J. Bouska, Vincent L. Giranda, Jonathan Greer, Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nature Biotechnology. ,vol. 18, pp. 1105- 1108 ,(2000) , 10.1038/80319
Thomas G. Davies, Rob L. M. van Montfort, Glyn Williams, Harren Jhoti, Pyramid: An Integrated Platform for Fragment‐based Drug Discovery Wiley‐VCH Verlag GmbH & Co. KGaA. pp. 193- 214 ,(2006) , 10.1002/3527608761.CH10
Stephen Roughley, Lisa Wright, Paul Brough, Andrew Massey, Roderick E. Hubbard, Hsp90 inhibitors and drugs from fragment and virtual screening. Topics in Current Chemistry. ,vol. 317, pp. 61- 82 ,(2011) , 10.1007/128_2011_181
Roderick E. Hubbard, James B. Murray, Experiences in fragment-based lead discovery. Methods in Enzymology. ,vol. 493, pp. 509- 531 ,(2011) , 10.1016/B978-0-12-381274-2.00020-0
N. Smirnov, Table for Estimating the Goodness of Fit of Empirical Distributions Annals of Mathematical Statistics. ,vol. 19, pp. 279- 281 ,(1948) , 10.1214/AOMS/1177730256
Philip J. Hajduk, Jeffrey R. Huth, Stephen W. Fesik, Druggability indices for protein targets derived from NMR-based screening data. Journal of Medicinal Chemistry. ,vol. 48, pp. 2518- 2525 ,(2005) , 10.1021/JM049131R
Gideon Bollag, James Tsai, Jiazhong Zhang, Chao Zhang, Prabha Ibrahim, Keith Nolop, Peter Hirth, Vemurafenib: the first drug approved for BRAF -mutant cancer Nature Reviews Drug Discovery. ,vol. 11, pp. 873- 886 ,(2012) , 10.1038/NRD3847
Paul A. Brough, Wynne Aherne, Xavier Barril, Jenifer Borgognoni, Kathy Boxall, Julie E. Cansfield, Kwai-Ming J. Cheung, Ian Collins, Nicholas G. M. Davies, Martin J. Drysdale, Brian Dymock, Suzanne A. Eccles, Harry Finch, Alexandra Fink, Angela Hayes, Robert Howes, Roderick E. Hubbard, Karen James, Allan M. Jordan, Andrea Lockie, Vanessa Martins, Andrew Massey, Thomas P. Matthews, Edward McDonald, Christopher J. Northfield, Laurence H. Pearl, Chrisostomos Prodromou, Stuart Ray, Florence I. Raynaud, Stephen D. Roughley, Swee Y. Sharp, Allan Surgenor, D. Lee Walmsley, Paul Webb, Mike Wood, Paul Workman, Lisa Wright, 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer Journal of Medicinal Chemistry. ,vol. 51, pp. 196- 218 ,(2007) , 10.1021/JM701018H
Wan F. Lau, Jane M. Withka, David Hepworth, Thomas V. Magee, Yuhua J. Du, Gregory A. Bakken, Michael D. Miller, Zachary S. Hendsch, Venkataraman Thanabal, Steve A. Kolodziej, Li Xing, Qiyue Hu, Lakshmi S. Narasimhan, Robert Love, Maura E. Charlton, Samantha Hughes, Willem P. van Hoorn, James E. Mills, Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics Journal of Computer-aided Molecular Design. ,vol. 25, pp. 621- 636 ,(2011) , 10.1007/S10822-011-9434-0
Robert A. Copeland, David L. Pompliano, Thomas D. Meek, Drug–target residence time and its implications for lead optimization Nature Reviews Drug Discovery. ,vol. 5, pp. 730- 739 ,(2006) , 10.1038/NRD2082